Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.21) by 176.19 percent. This is a 6.45 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $1.779 million which missed the analyst consensus estimate of $1.897 million by 6.20 percent. This is a 18.84 percent increase over sales of $1.497 million the same period last year.